Related Experiment Video
Updated: Jul 2, 2026
Integration of Electroporation in Urological Practice: Design and Evaluation of a New Transurethral Electrode
Published on: March 20, 2026
Irreversible electroporation in focal therapy for prostate cancer: current status and future directions
Francisco O Durazo-Ruiz1, Rocío Roldán-Testillano1, Lara Rodriguez-Sanchez2
1Department of Urology, McGill University Health Centre, Montréal, Canada.
Abstract:
The treatment of prostate cancer (PCa) requires approaches that eliminate malignant tissue while preserving essential urinary and sexual functions. Irreversible electroporation (IRE) represents a targeted ablative strategy that disrupts cellular membrane integrity through precise electrical pulses, demonstrating the capacity to ablate cancerous foci while sparing adjacent neurovascular bundles and sphincter mechanisms. This structured review examines the mechanistic foundations of IRE technology, evaluates current clinical evidence regarding safety and efficacy, and explores promising applications that may redefine precision urologic care. Existing clinical studies demonstrate encouraging oncological control rates with superior preservation of continence and erectile function compared to whole-gland treatments, though patient selection criteria and long-term durability remain areas requiring further investigation. Emerging applications include salvage therapy following radiation failure, integration with advanced multiparametric imaging for precision targeting, and combination strategies with systemic therapies. The regulatory approval status and economic implications of IRE implementation vary significantly across healthcare systems, creating disparities in patient access and adoption of this technology that must be addressed to ensure equitable availability of focal ablation options. As the technology matures, establishing standardized treatment protocols, refining patient selection algorithms, and conducting robust comparative effectiveness studies will be essential to define the optimal role of IRE within prostate cancer management.
Insights
Irreversible electroporation (IRE) offers precise prostate cancer (PCa) ablation, preserving function. Studies show good oncological control and better continence/erectile function than whole-gland treatments.
Area of Science:
- Urology
- Oncology
- Medical Technology
Background:
- Prostate cancer (PCa) treatment necessitates balancing tumor eradication with preserving urinary and sexual functions.
- Irreversible electroporation (IRE) is a focal ablation technique using electrical pulses to disrupt cancer cell membranes.
- This method aims to spare critical surrounding structures like neurovascular bundles and sphincter mechanisms.
Purpose of the Study:
- To review the mechanisms of IRE technology in prostate cancer treatment.
- To evaluate current clinical evidence on the safety and efficacy of IRE for PCa.
- To explore emerging applications and future directions for IRE in precision urologic care.
Main Methods:
- Structured literature review of IRE technology in prostate cancer.
- Analysis of mechanistic foundations and clinical studies on safety and efficacy.
- Exploration of current and potential future applications of IRE.
Main Results:
- Clinical studies indicate encouraging oncological control rates with IRE.
- IRE demonstrates superior preservation of continence and erectile function compared to whole-gland treatments.
- Further investigation is needed for patient selection criteria and long-term durability.
Conclusions:
- IRE shows promise as a precision ablative strategy for prostate cancer, enhancing functional outcomes.
- Emerging applications include salvage therapy, image-guided targeting, and combination treatments.
- Standardized protocols, refined patient selection, and comparative studies are crucial for defining IRE's role in PCa management.
